HGF (Hepatocyte Growth Factor): MET Receptor Kinase Biology, Gab1 Scaffold Signaling, Invasion, and Selective Research Tools

# HGF (Hepatocyte Growth Factor): MET Receptor Kinase Biology, Gab1 Scaffold Signaling, Invasion, and Selective Research Tools

Category: Peptide Guides | Read Time: 14 min | Tags: HGF, MET, scatter factor, Gab1, SHP2, invasion, EMT, crizotinib, tepotinib, capmatinib, MET amplification, c-Met

---

For Research Use Only. Not for human or animal therapeutic use.

---

Introduction

Hepatocyte growth factor (HGF), alternatively known as scatter factor (SF) due to its ability to dissociate tightly packed epithelial colonies, is a large multidomain glycoprotein that signals exclusively through the MET receptor tyrosine kinase to drive an extraordinarily diverse set of biological programs — liver regeneration, kidney tubulogenesis, branching morphogenesis in multiple organs, wound healing, neuronal survival, muscle progenitor migration, and, pathologically, tumor invasion, metastasis, and resistance to virtually every class of targeted cancer therapy.

What makes HGF/MET mechanistically unique among growth factor systems is the scatter program: a coordinated cell-biological response involving simultaneously increased motility, disruption of cell-cell adhesion, ECM invasion, and polarized tubulogenesis that EGFR, VEGFR, FGFR, and IGF1R individually cannot replicate. This scatter program is encoded in the MET signaling architecture — particularly through the Gab1 scaffold, which creates an exceptional PI3K/SHP2/Rac1 signaling cluster that drives lamellipodia extension and matrix invasion simultaneously. This review covers HGF propeptide processing, MET receptor structure, Gab1-centric signaling, biological programs (branching morphogenesis, scatter, EMT), MET oncogenic alterations (amplification, activating mutations, gene fusions), EGFR resistance bypass (the mechanism covered briefly in the EGF article in this series), and selective research tools for MET modulation.

---

HGF Gene Organization and Propeptide Processing

Human HGF maps to chromosome 7q21.11 and encodes an ~728-amino-acid preproprotein structurally related to plasminogen and other kringle-domain serine protease precursors. Unlike most growth factors, HGF is synthesized as an inactive single-chain precursor (pro-HGF; ~90 kDa) that must be proteolytically cleaved by serine proteases to generate the active heterodimer.

Domain Architecture of Pro-HGF and Mature HGF

Pro-HGF has an N-terminal signal peptide followed by:

• •N-terminal domain (N domain, ~40 aa): bivalent HGF receptor-binding hairpin that contributes to high-affinity MET engagement; also termed the "NK1" region when expressed in isolation
• •Four kringle domains (K1–K4): ~80 aa each; disulfide-stabilized triple-loop structures characteristic of fibrinolytic factors; K1 mediates heparan sulfate binding (HSPG co-receptor, similar to FGF-2)
• •Serine protease-like domain (SPH): C-terminal domain homologous to serine proteases but catalytically inactive (Asp→Glu, Ser→Tyr, His→Gln substitutions that ablate protease activity); contains the primary MET sema-domain binding contact

Proteolytic activation: Furin (intracellular, Golgi) or extracellular serine proteases (HGF activator/HGFA, matriptase/MT-SP1, hepsin, TMPRSS2) cleave pro-HGF at Arg494-Val495, generating a disulfide-linked two-chain mature HGF (α-chain ~69 kDa + β-chain ~34 kDa). Only the two-chain form is a full MET agonist — the uncleaved single-chain pro-HGF binds MET with lower affinity and functions as a partial agonist or antagonist depending on concentration.

NK1 and NK2 natural splice variants: NK1 (N + K1 domains) is a heparin-dependent partial agonist; NK4 (N + K1 + K2 + K3 + K4) is a competitive MET antagonist used experimentally to block HGF signaling without affecting MET kinase activity directly.

---

MET Receptor Structure and Activation

MET (gene MET, chr7q31) is a disulfide-linked αβ heterodimeric receptor tyrosine kinase with unusual extracellular domain architecture:

Extracellular Domain

• •Sema domain (~500 aa): the primary HGF-binding domain; contains a 7-bladed β-propeller fold; occupies the α-subunit and N-terminal portion of the β-subunit. The Sema domain of MET contacts both the N domain and the SPH domain of HGF simultaneously, creating a bivalent high-affinity interaction (Kd ~0.1–1 nM for mature two-chain HGF).
• •PSI domain (plexin-semaphorin-integrin): ~50 aa cysteine-rich domain bridging Sema to IPT domains
• •4 IPT domains (immunoglobulin-like fold in plexins and transcription factors): stalk region between Sema and transmembrane helix; contributes to ligand-induced dimerization

Intracellular Domain

• •Juxtamembrane (JM) domain: contains Tyr1003 (Cbl binding site for receptor ubiquitination/degradation) and Ser985 (PKC-mediated negative regulatory phosphorylation)
• •Kinase domain: activation loop Tyr1234/Tyr1235 (equivalent to EGFR Tyr1068; primary kinase activation phosphorylation)
• •Multifunctional docking site (MDS; C-tail): Tyr1349/Tyr1356 are the critical bidentate docking tyrosines that recruit Gab1, Grb2, Shc, SHP2, Src, STAT3, PI3K p85 directly — an unusually compact signal amplification node for a single docking region

Ligand-Induced Dimerization Mechanism

Unlike EGFR (monomer→dimer) or IGF1R (pre-formed tetramer), MET exists primarily as a monomer in the basal state and dimerizes upon HGF binding. The two-chain HGF functions as a 2:2 bivalent bridge — the N domain of one HGF chain contacts MET sema domain, while the SPH domain contacts a second MET sema domain — inducing homodimerization of two MET monomers. Heparan sulfate proteoglycans (syndecan-1, perlecan) enhance HGF-driven MET dimerization by co-concentrating HGF at the pericellular matrix surface, analogous to the FGF-2/HSPG/FGFR ternary complex.

---

The Gab1 Scaffold: Master Signal Integrator of MET

The defining feature of MET signaling — what distinguishes the HGF/MET scatter program from other RTK responses — is the Gab1 (Grb2-associated binder 1) scaffold. Gab1 is a 694-amino-acid pleckstrin homology (PH)-domain-containing scaffold protein that creates an exceptional signal amplification platform at the MET docking site.

Gab1 Recruitment to MET

Gab1 is recruited to activated MET through two parallel mechanisms:

1. Direct binding: MET pTyr1349/pTyr1356 bidentate docking site directly binds the Gab1 MBD (MET binding domain, ~13-aa region unique among Gab family members) with high affinity and selectivity

2. Indirect Grb2-mediated: Grb2 (bound to MET pTyr1356 via SH2) recruits Gab1 via Grb2's SH3 domain binding to PXXP motifs in Gab1

Gab1 also contains a PH domain that binds PIP3 — creating a positive feedback loop where PI3K (activated by Gab1) generates PIP3 that recruits more Gab1, amplifying and sustaining the signaling complex at the membrane.

Gab1 Docking Sites and Effectors

Once recruited to MET and membrane-anchored via PIP3/PH, Gab1 is phosphorylated by MET kinase on multiple tyrosines:

• •Tyr447/Tyr472/Tyr589 → recruit p85/PI3K → PIP3 → Akt → cell survival, proliferation, tubulogenesis
• •Tyr627/Tyr659 → recruit SHP2 (PTPN11) phosphatase → Ras-GEF activation (SHP2 dephosphorylates RasGAP docking sites on receptors, liberating Ras-GDP for GEF exchange) → RAS → ERK1/2 → motility, proliferation
• •Tyr307/Tyr373 → recruit PLCγ → IP3/DAG → Ca²⁺/PKC → cytoskeletal reorganization

SHP2: The RAS Activator in the Gab1 Complex

SHP2's role at the Gab1 scaffold is primarily adaptor/de-phosphorylation of negative regulators rather than canonical phosphatase activity on direct substrates. Key SHP2 actions:

• •Dephosphorylation of Sprouty proteins (SPRY2 → Grb2 sequestration is relieved → Sos → Ras)
• •Dephosphorylation of paxillin → focal adhesion reorganization
• •Direct activation of C3G GEF → Rap1-GTP → integrin activation (lamellipodia extension)

SHP2 is also the effector of the oncogenic SHP2 mutations (E76K, A72V) found in Noonan syndrome and juvenile myelomonocytic leukemia — providing a disease-relevant angle for SHP2 inhibitors (RMC-4550, TNO155) in HGF/MET pathway research.

Gab1-PI3K-Rac1: The Scatter Effector Axis

The specific HGF scatter program requires simultaneous activation of:

1. Rac1 (via PI3K→PREX1 or TIAM1 → Rac-GTP): drives lamellipodia (broad, flat protrusions); requires sustained PIP3 at the leading edge

2. Cdc42 (via Gab1-PLCγ-PKCζ): drives filopodia (thin actin protrusions for directional sensing)

3. RhoA downregulation (via p190RhoGAP, activated by Src/Gab1): reduces stress fibers and cell-cell junction tension

This Rac1↑/RhoA↓/Cdc42↑ balance constitutes the cytoskeletal signature of HGF-driven scatter. EGFR stimulation, by contrast, predominantly activates Rac1 without the coordinate RhoA downregulation — explaining why EGF drives directional migration but not full scatter (colony dissociation).

---

Biological Programs Driven by HGF/MET

Liver Regeneration

MET is expressed at high levels in hepatocytes, and HGF produced by hepatic stellate cells and sinusoidal endothelium is the primary mitogen for hepatocyte regeneration after partial hepatectomy. Liver-specific MET conditional knockout mice (albumin-Cre × MET-flox) have severely impaired liver regeneration — they survive but exhibit delayed and incomplete hepatocyte repopulation after 70% hepatectomy (Huh et al., PNAS, 2004), establishing MET as the non-redundant hepatocyte mitogen in vivo.

Branching Morphogenesis

In kidney, lung, mammary gland, and pancreas, HGF/MET drives branching tubulogenesis — the process by which simple epithelial sheets form complex branched ductal networks. In 3D collagen or Matrigel culture, MDCK cells (the classic branching morphogenesis model) form hollow tubular cysts with branches exclusively in response to HGF, not EGF or FGF-2. The tubulogenesis requires Gab1 — Gab1-deleted MDCK cells retain proliferative responses to HGF but completely fail to form tubular structures (Weidner et al., Nature, 1996; Maroun et al., Mol Cell Biol, 1999).

Muscle Progenitor Migration

MET is expressed on muscle satellite cells and embryonic muscle progenitors. HGF from the myotome drives migration of MET+ progenitors to limb bud positions for distal limb muscle formation. MET or HGF knockout mice lack all limb muscles — the most dramatic developmental phenotype from loss of a single growth factor/receptor pair (Bladt et al., Nature, 1995).

Neuronal Survival and Axon Guidance

HGF promotes survival of motor neurons, sensory neurons, and dopaminergic neurons via MET/PI3K/Akt. In the developing CNS, HGF acts as an axon guidance cue for specific motor neuron populations and promotes interneuron migration in the cortex. MET expression in cortical interneurons is required for normal GABAergic circuit formation — links have been proposed between MET promoter polymorphisms and autism spectrum disorder risk (Campbell et al., PNAS, 2006).

---

HGF/MET in Cancer: Invasion, Metastasis, and Therapy Resistance

Autocrine and Paracrine HGF Loops

In most epithelial cancers, MET is expressed on tumor cells while HGF is produced by cancer-associated fibroblasts (CAFs) — a paracrine signaling architecture analogous to the VEGF-C/lymphatic endothelium axis. Some tumor types (glioblastoma, certain sarcomas) establish autocrine HGF loops where tumor cells produce both HGF and MET.

MET Amplification

MET gene amplification (chromosome 7q31 polysomy or focal high-level amplification) drives constitutive MET dimerization and kinase activation independently of HGF ligand. Key cancer contexts:

• •NSCLC: MET amplification in 3–5% of treatment-naive tumors; 15–20% of EGFR TKI-resistant tumors (the ErbB3 bypass mechanism described in the EGF article)
• •Gastric cancer: MET amplification in 5–10% (defines a distinct molecular subtype with poor prognosis)
• •Esophageal adenocarcinoma: 10–20% MET amplification; associated with HER2 co-amplification
• •Colorectal cancer: ~2–4% focal MET amplification, distinct from polysomy

In amplified contexts, MET inhibitors (capmatinib, tepotinib) have demonstrated high response rates, validating MET amplification as a true driver — predictive biomarker work defines high-level amplification (≥5 MET copies or MET/CEP7 ratio ≥2) as the threshold for MET inhibitor sensitivity.

MET Exon 14 Skipping Mutations

MET exon 14 encodes the juxtamembrane domain including Tyr1003 (CBL E3 ubiquitin ligase binding site). Exon 14 skipping mutations delete the Tyr1003 CBL binding site, impairing receptor ubiquitination and lysosomal degradation → prolonged MET surface retention → sustained downstream signaling with normal ligand concentrations. MET exon 14 alterations occur in ~3–4% of NSCLC and define a MET-addicted subtype sensitive to MET TKIs (tepotinib, capmatinib both approved for this indication, but we focus on their research tool utility).

MET Activating Mutations

Point mutations in the MET kinase domain (M1268T, Y1248H, D1228H, V1110I) activate MET constitutively; found predominantly in hereditary and sporadic papillary renal cell carcinoma type 1 (PRCC1) — where germline MET activating mutations define the syndrome.

MET/HGF in Invasion and EMT

HGF is the most potent single-factor inducer of cell scatter and invasion in epithelial cell models:

• •SNAI1 (Snail) and TWIST transcription via ERK1/2 (Gab1→SHP2→RAS→ERK→AP-1) → E-cadherin repression → cell-cell junction breakdown
• •MMP-1, MMP-2, MMP-9 induction via ERK/AP-1 → BM degradation → invasive front formation
• •αvβ6 integrin upregulation → TGF-β1 activation (as described in the TGF-β1 article) → further EMT amplification
• •Paxillin/focal adhesion kinase (FAK) Tyr397/Tyr925 phosphorylation via Src-Gab1 → focal adhesion turnover → traction force cycling for amoeboid migration

---

Selective MET Research Tools

Type Ia MET Kinase Inhibitors (ATP-Competitive, Type I Binding)

Crizotinib (PF-02341066; Sigma PZ0298): Originally developed as a MET inhibitor before its ALK inhibitor activity was discovered; IC50 ~8 nM (MET), ~20 nM (ALK), ~75 nM (ROS1). Crizotinib is a multi-kinase tool for studying MET + ALK simultaneously; selectivity must be accounted for with ALK-expressing cells. Working concentration: 100 nM–1 µM for MET inhibition (confirm with pMET and pALK status).

Type Ib MET Kinase Inhibitors (Selective)

Capmatinib (INC280; Sigma SML2842): Highly selective MET inhibitor; IC50 ~0.13 nM (MET enzymatic); >10,000-fold selectivity over most other kinases; negligible ALK, VEGFR, EGFR activity. The most selective MET tool compound commercially available. Working concentration: 1–100 nM for cellular MET blockade in MET-amplified cells; 100 nM–1 µM for MET exon 14 skipping models. Standard for isolating MET-specific signaling from multi-kinase crizotinib results.

Tepotinib (EMD1214063; MedChemExpress HY-10433): Highly selective MET inhibitor; IC50 ~1 nM (MET); >500-fold selectivity; approved for MET exon 14 skipping NSCLC (research utility: MET-selective blockade in complex co-culture or organoid models). Use at 10–500 nM.

Savolitinib (AZD6094, volitinib): MET-selective; IC50 ~5 nM; particularly validated in papillary renal cell carcinoma MET-mutant models; 50–500 nM working concentration.

SU11274: Earlier-generation MET kinase inhibitor; IC50 ~10 nM; less selective than capmatinib/tepotinib but inexpensive and widely available (Sigma S9820); useful for general MET pathway characterization experiments at 1–10 µM.

Anti-MET Antibodies

Onartuzumab (MetMAb; one-armed anti-MET): Monovalent anti-MET antibody that blocks HGF binding without crosslinking two MET molecules (bivalent anti-MET antibodies would activate MET by inducing dimerization — onartuzumab's monovalency prevents this). Research use: 1–10 µg/mL for paracrine HGF-driven MET activation experiments where ligand-level blockade is preferred over kinase inhibitor use.

Anti-MET antibodies for detection (non-blocking): Cell Signaling #8198 (clone D1C2, rabbit mAb, WB/IHC/IP), Cell Signaling #3127 (for pMET Y1234/Y1235 detection — the standard phospho-MET antibody for WB).

Anti-HGF Antibodies and NK4 Tool

Anti-human HGF neutralizing antibody (R&D Systems MAB294): Blocks HGF binding to MET; IC50 ~0.4 µg/mL in bioassay; use at 2–20 µg/mL for conditioned medium HGF neutralization.

NK4 recombinant protein (N+K1+K2+K3+K4 domains of HGF): Competitive MET antagonist that binds MET with high affinity but does not activate it (incomplete MET-dimerizing geometry); IC50 for HGF competition ~3–10 nM; use at 100–1000 ng/mL. NK4 is the only tool that selectively blocks HGF binding at the receptor level without affecting MET kinase activity per se — useful for dissecting ligand-dependent from ligand-independent (amplification-driven) MET signaling.

MET Pathway Downstream Tools

• •SHP099 (SHP2 inhibitor; Sigma SML2286): Allosteric SHP2 inhibitor; IC50 ~70 nM; blocks SHP2-mediated RAS activation downstream of Gab1; useful for isolating SHP2/ERK branch from PI3K/Akt branch of HGF signaling. Use at 1–10 µM.
• •NSC-87877 (SHP2 inhibitor): Older, less selective SHP2 inhibitor; competitive with substrate binding; IC50 ~5 µM; use only when SHP099 is unavailable.
• •Rac1 inhibitor (NSC23766; Sigma 553514): Blocks Rac1-GEF interaction (TIAM1/Rac1); IC50 ~50 µM; use at 100–200 µM to abolish HGF-driven lamellipodia formation and scatter while preserving ERK/Akt signaling.
• •Y-27632 (ROCK inhibitor; Sigma Y0503): At 10 µM, blocks RhoA/ROCK-mediated stress fibers without affecting MET/Gab1 signaling; useful for dissecting RhoA-dependent from Rac1-dependent cytoskeletal reorganization in HGF-treated cells.

Recombinant HGF Protein

R&D Systems 294-HG (human HGF, two-chain active form): The standard research-grade HGF for MET activation assays; produced in CHO cells; N-glycosylated (unlike most growth factors — HGF glycosylation contributes ~10% to MET affinity). EC50 for cell scatter ~0.1–1 ng/mL; for proliferation ~1–10 ng/mL; for Akt phosphorylation ~0.5–5 ng/mL. Storage: −80°C in PBS + 0.1% BSA at 100 µg/mL.

HGFA (HGF activator) recombinant (R&D Systems 2707-SE): The primary serine protease activating pro-HGF; use at 1–10 nM with pro-HGF to generate active HGF in defined systems; validate conversion by SDS-PAGE (pro-HGF single band ~90 kDa → two bands ~69 + ~34 kDa after activation).

---

Experimental Protocols for HGF/MET Research

Protocol 1: HGF-Driven MET Phosphorylation and Gab1 Scaffold Assembly

1. Starve cells (MDCK, H1993 MET-amplified NSCLC, or primary hepatocytes) in serum-free medium 4–6h.

2. Stimulate with HGF (10–50 ng/mL) for 5, 15, 30, 60 min.

3. Lyse in MET immunoprecipitation buffer (25 mM HEPES pH 7.4, 150 mM NaCl, 1% Triton X-100, 10% glycerol + phosphatase + protease inhibitors).

4. Western blot: pMET Y1234/Y1235 (Cell Signaling #3077, 1:1000), total MET (#8198, 1:1000), pGab1 Y627 (Cell Signaling #3233, 1:1000), pSHP2 Y542 (Cell Signaling #3751, 1:1000), pAkt S473 (#4060, 1:2000), pERK1/2 (#4370, 1:2000).

5. Capmatinib (10 nM, 30 min pre-treatment) as positive inhibition control; NK4 (500 ng/mL) as ligand competition control.

Protocol 2: HGF-Driven Scatter (Colony Dissociation) Assay

1. Seed MDCK or A549 cells at low density (500–1000 cells/well, 6-well plate) in full medium; allow colony formation for 48–72h until compact colonies of 20–100 cells form.

2. Replace medium with serum-free medium ± HGF (10–50 ng/mL) ± capmatinib (10–100 nM) ± NSC23766 (100 µM, Rac1 inhibitor).

3. Image colonies at 0, 6, 12, 24h. Quantify: colony compactness score (Image J: ratio of colony perimeter to area; scattered colonies have higher perimeter-to-area ratio), or count scattered single cells vs. colony-associated cells manually.

4. Parallel wells: phase-contrast time-lapse imaging (1 image/30 min) captures real-time scatter kinetics.

5. Expected: HGF drives complete scatter (all cells separate) at 24h; capmatinib blocks; NSC23766 partially blocks (Rac1-dependent component confirmed; SHP2/ERK component contributes residually).

Protocol 3: 3D Tubulogenesis in Collagen/Matrigel

1. Prepare 1 mg/mL rat tail collagen I gel (pH 7.4, neutralized) or Matrigel (growth-factor-reduced, diluted 1:1 with collagen) in 96-well or chamber slides.

2. Embed 500–2000 MDCK cells per well as single cells or small aggregates; overlay with collagen layer.

3. Add complete medium ± HGF (10–50 ng/mL) ± capmatinib (10 nM) ± wortmannin (100 nM, PI3K blockade to test tubulogenesis PI3K-dependence).

4. Image every 24h for 5–7 days; quantify: % cells forming tubular structures, average tube length, branching number per structure.

5. Expected: HGF drives tubular cyst formation with branching; capmatinib prevents tubulogenesis (collapses into solid spheroids or no growth); wortmannin blocks tubulogenesis without affecting scatter (PI3K-selective tubulogenesis requirement).

Protocol 4: MET Amplification Detection by FISH and Western Blot

1. FISH (fluorescence in situ hybridization): MET FISH probe (Agilent FISH probe panel or Vysis MET/CEP7 dual-color probe); prepare FFPE cell blocks or cytospin of suspension cells; hybridize per manufacturer; acquire with fluorescence microscope; count MET and CEP7 (chromosome 7 centromere reference) signals in ≥20 nuclei; calculate MET/CEP7 ratio. Threshold for amplification: ≥2.0 (focal) or average MET signals ≥5/cell.

2. Western blot quantification: In MET-amplified cells, total MET protein is proportionally elevated vs. non-amplified controls; quantify MET/GAPDH ratio by densitometry; validate with cells of known amplification status (H1993: high amplification; EBC-1: moderate amplification; H1299: non-amplified control).

3. Gene copy number by digital PCR (ddPCR): Design MET exon 14/15 primers and CEP7 reference amplicon; run on ddPCR system; calculate copy number ratio. Most quantitative but requires ddPCR equipment.

Protocol 5: HGF/MET-Driven Invasion (Matrigel Transwell)

1. Coat 8 µm Transwell inserts (Corning 3422) with Matrigel (growth-factor-reduced, 200 µg per insert in PBS; dry overnight; rehydrate 1h at 37°C).

2. Upper chamber: 5 × 10⁴ serum-starved cells in 100 µL serum-free medium ± capmatinib (100 nM).

3. Lower chamber: 600 µL serum-free medium + HGF (50 ng/mL) as chemoattractant.

4. Incubate 16–24h at 37°C; remove non-invaded cells with cotton swab; fix with 4% PFA; stain crystal violet; count invaded cells in 5 random fields at 10×.

5. Controls: no HGF lower chamber (basal invasion), no Matrigel (migration assay), capmatinib both chambers (complete blockade), SHP099 (10 µM) to confirm SHP2/RAS/ERK contribution to invasion.

---

HGF/MET and EGFR Resistance: The Gab1 Bypass Circuit

As noted in the EGF article (see EGFR/ErbB series) and the IGF-1 article in this series, MET amplification mediates EGFR TKI resistance by phosphorylating and activating ErbB3. The key downstream mechanism:

MET (amplified, ligand-independent) → phosphorylates Gab1 → Gab1 recruits p85/PI3K → PIP3 → Akt: this restores PI3K/Akt signaling even when EGFR kinase is fully inhibited by gefitinib/erlotinib. The critical experiment (Engelman et al., Science, 2007) showed that anti-ErbB3 antibody co-treatment with gefitinib suppressed the MET-amplified bypass, implicating ErbB3 as the obligate PI3K amplifier in the bypass circuit. Capmatinib + gefitinib (or osimertinib for T790M-acquired resistance cases with secondary MET amplification) combination is therefore the mechanistic test of MET bypass in EGFR TKI resistance research.

---

Key Research Tools Summary

---

Conclusion

HGF/MET defines a unique signaling paradigm in RTK biology: a multi-domain kringle-containing ligand that requires extracellular proteolytic activation, a receptor that engages that ligand through a bivalent sema-domain contact, and a Gab1 scaffold that transforms MET kinase activity into a coordinated scatter/invasion program through simultaneously activated PI3K/Rac1, SHP2/ERK, and PLCγ/Ca²⁺ effector branches. No other RTK-ligand pair drives the coordinated cell-biological scatter and tubulogenesis programs of HGF/MET — a biological uniqueness that reflects the dedicated architecture of the Gab1 scaffold and the unusual spatial organization of signaling that results from PIP3/PH-driven membrane recruitment and MBD/pTyr1349-1356 docking.

In cancer biology, MET amplification and exon 14 skipping have emerged as actionable oncogenic events, while MET-mediated EGFR bypass resistance remains one of the most clinically important resistance mechanisms to address. Selective research tools — particularly capmatinib (MET-selective kinase inhibitor), onartuzumab (non-agonistic ligand-blocking antibody), NK4 (competitive antagonist without kinase inhibition), and SHP099 (allosteric SHP2 inhibitor) — now allow mechanistic dissection of individual MET signaling branches with the precision needed to understand context-dependent pathway biology in complex co-culture, organoid, and tumor microenvironment research models.

---

References

1. Bhatt DL, et al. (Scatter factor history): Stoker M, et al. Scatter factor is a fibroblast-derived modulator of epithelial cell motility. Nature. 1987;327(6119):239–242.

2. Weidner KM, et al. Interaction between Gab1 and the c-Met receptor tyrosine kinase is responsible for epithelial morphogenesis. Nature. 1996;384(6605):173–176.

3. Bladt F, et al. Essential role for the c-met receptor in the migration of myogenic precursor cells into the limb bud. Nature. 1995;376(6543):768–771.

4. Huh CG, et al. Hepatocyte growth factor/c-met signaling pathway is required for efficient liver regeneration and repair. PNAS. 2004;101(13):4477–4482.

5. Engelman JA, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science. 2007;316(5827):1039–1043.

6. Campbell DB, et al. A genetic variant that disrupts MET transcription is associated with autism. PNAS. 2006;103(45):16834–16839.

7. Birchmeier C, et al. Met, metastasis, motility and more. Nat Rev Mol Cell Biol. 2003;4(12):915–925.

8. Gherardi E, et al. Targeting MET in cancer: rationale and progress. Nat Rev Cancer. 2012;12(2):89–103.

9. Maroun CR, et al. The Gab1 PH domain is required for localization of Gab1 at sites of cell-cell contact and epithelial morphogenesis downstream from the met receptor tyrosine kinase. Mol Cell Biol. 1999;19(3):1784–1799.

10. Wolf-Yadlin A, et al. Effects of HER2 overexpression on cell signaling networks governing proliferation and migration. Mol Syst Biol. 2006;2:54.